Out-of-specification (OOS) results were found in retention samples for atomoxetine content and, for batch 1304011, also for mass uniformity; the impact of this non‑conformity on the drug’s efficacy and safety cannot be determined. Potential effects: reduced treatment efficacy or unpredictable adverse effects.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use Konaten capsules from the listed batches. Patients should check the batch number on the packaging, consult their doctor or pharmacist about further therapy, and, if appropriate, return the ...
The Chief Pharmaceutical Inspector suspended distribution of selected batches of Konaten (Atomoxetine), hard capsules throughout the country and granted the decision immediate enforceability.
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related